A hospital cost analysis of a fibrin sealant patch in soft tissue and hepatic surgical bleeding

Abstract

BackgroundDespite hemostat use, uncontrolled surgical bleeding is prevalent. Drawbacks of current hemostats include limitations with efficacy on first attempt and suboptimal ease-of-use. Evarrest® is a novel fibrin sealant patch that has demonstrated high hemostatic efficacy compared with standard of care across bleeding severities. The objective of this study was to conduct a hospital cost analysis of the fibrin sealant patch versus standard of care in soft tissue and hepatic surgical bleeding.MethodsThe analysis quantified the 30-day costs of each comparator from a hospital perspective. Published US unit costs were applied to resource use (ie, initial treatment, retreatment, operating time, hospitalization, transfusion, and ventilator) reported in four trials. A “surgical” analysis included resources clinically related to the hemostatic benefit of the fibrin sealant patch, whereas a “hospital” analysis included all resources reported in the trials. An exploratory subgroup analysis focused solely on coagulopathic patients defined by abnormal blood test results.ResultsThe surgical analysis predicted cost savings of $54 per patient with the fibrin sealant patch compared with standard of care (net cost impact: −$54 per patient; sensitivity range: −$1,320 to $1,213). The hospital analysis predicted further cost savings with the fibrin sealant patch (net cost impact of −$2,846 per patient; sensitivity range: −$1,483 to −$5,575). Subgroup analyses suggest that the fibrin sealant patch may provide dramatic cost savings in the coagulopathic subgroup of $3,233 (surgical) and $9,287 (hospital) per patient. Results were most sensitive to operating time and product units.ConclusionIn soft tissue and hepatic problematic surgical bleeding, the fibrin sealant patch may result in important hospital cost savings.

Cerebrospinal fluid leakage costs after craniotomy and health economic assessment of incidence reduction from a hospital perspective in the Netherlands

“…3 4 The costs for an external ventricle drain and external lumbar drain and dural sealants were based on the existing literature and local prices. 5 Costs for cranial surgery and reoperation were determined based on operating room time multiplied by cost per minute (€10.59). 6 All costs are presented in 2018 Euros.…”

A Study of Safety and Effectiveness of Evicel Fibrin Sealant as an Adjunctive Hemostat in Pediatric Surgery

“…4,5 THA are known to improve patient outcome and reduce health care cost. [6][7][8] Classified by mechanism of action, they include mechanical agents that provide a structural matrix, active agents that contain thrombin, flowable consisting of gelatin matrix with/without thrombin, and fibrin sealants (FSs) that are based on fibrinogen and thrombin. 4,5 FSs have emerged as effective and safe adjuncts for controlling perioperative bleeding in a wide range of open and endoscopic surgical scenarios.…”

Safety and Hemostatic Effectiveness of SURGICEL® Powder in Mild and Moderate Intraoperative Bleeding

“…By reducing surgical time and surgical complications, they ultimately optimize patient health and reduce health care costs. 2 , 8 , 9 A variety of absorbable topical hemostatic agents are available, which differ in physicochemical properties and mode of action, as well as in ease of use, safety, and cost. The optimal choice of agent depends on the surgical scenario and bleeding situation (visibility, anatomy, and access) and on the patient's coagulation and comorbidity status.…”